Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face

Inclusion Criteria: * Women aged 30 to 50 years old, inclusive. * Mild, moderate or severe expression wrinkles. * Patients who had understood and signed the Informed Consent Form. Exclusion Criteria: * Subjects treated with botulinum toxin on the upper third of the face within the previous 6-month period; * Former implantation of permanent material and surgery (scars). * Use of any anticoagulant agent up to 7 days prior to the investigational product application; * Concomitant use of aminoglycosides or of any other drug that may impair in the neuromuscular transmission; * Coagulopathies and local inflammation/ infection at the application site. * Diseases which do impact on the neuromuscular function, such as: myasthenia gravis, Eaton Lambert Syndrome; * Pregnancy or breast feeding, women with potential to become pregnant or who do not agree to use an effective contraception method (Pearl Index \< 1%); * Allergy or known sensitivity to any of the components of the investigational drug; * Subjects who were enrolled in other clinical trial for the last 12-month period prior to the present study, as per Resolution 251/97; * Subjects who disagree with the study procedures, who do not sign the Informed Consent Form or who are not committed to participate in the trial.